Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP (CDM 60923-511-20) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved June 26, 2026 , from http://ppman.hank.ai/transparency/procedure/60923-511-20/by-state?code_type=CDM
“DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP (CDM 60923-511-20) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/60923-511-20/by-state?code_type=CDM. Accessed
June 26, 2026 .
“DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP (CDM 60923-511-20) by State,” HANK Price Transparency ,
accessed June 26, 2026 ,
http://ppman.hank.ai/transparency/procedure/60923-511-20/by-state?code_type=CDM.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
CDM · across United States
60923-511-20 — Delandistrogene Moxeparvovec-rokl 1.33x10exp13 Vg/ml Intravenous Susp
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$1,917,628
National median
$1,273,640 – $1,917,628
IQR (p25 – p75)
3
hospitals filing
2
states
Walking in without insurance?
Cash / self-pay price
Cash median
$2,496,000
vs. negotiated
+30.2%
Hospitals reporting
3
Cash / self-pay rates apply when you don't run the bill through insurance.
Many hospitals also offer income-based discounts on top of the published
cash price — always ask about a financial-assistance application
before paying.
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for 60923-511-20 (CDM), with interquartile range
State Median p25 p75
CT $1,917,628 $1,917,628 $1,917,628
RI $1,300,135 $815,763 $1,824,000